TOR1 AIP1 Interacts with P53 to Enhance Cell Cycle Dysregulation in Prostate Cancer Progression

Researchers analyzed the expression and survival data of TOR1 AIP1 in prostate adenocarcinoma (PRAD) patients in the TCGA database and verified the low expression of TOR1 AIP1 in prostate cancer by qPCR, western blot and immunohistology, which was correlated with the tumor stage and survival prognosis of PRAD.